This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Treatment selection considerations
Quality and duration of response to previous therapy are important prognostic factors when treating patients with MM2
Patient-related
factors
- Age
- Performance status
- Renal insufficiency
- Other comorbidities
- Cardiac
- Diabetes
- Neuropathy
- Cost/
socioeconomics
Disease-related
factors
- R-ISS staging
- Biochemical vs symptomatic relapse
- Disease tempo
- Extramedullary disease
- Functional high-risk MM
Treatment-related
factors
- History of prior exposure
- Monotherapy vs combination therapy
- Mode of administration
- Cost
- Toxicity profile
MM, multiple myeloma; R-ISS, Revised International Staging System.
1. Mikhael JR. Hematology Am Soc Hematol Educ Program. 2014(1);262-267. 2. Palumbo A, et al. N Engl J Med. 2011;364(11):1046-1060.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.